A RANDOMIZED, CONTROLLED, OPEN-LABEL, PHASE 2 STUDY OF CEMIPLIMAB AS A SINGLE AGENT AND IN COMBINATION WITH RP1 IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

Registry ID

RPL-002-18

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

REPLIMUNE, INC.

Start date

2022-08-10

Last update

2020-10-15

Conditions

• SQUAMOUS CELL CARCINOMA

Related clinical trials

• A PHASE 1 FIRST-IN-HUMAN, OPEN-LABEL STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV-711 AS A MONOTHERAPY OR IN COMBINATION WITH BUDIGALIMAB (ABBV-181) IN ADULT SUBJECTS WITH ADVANCED SQUAMOUS TUMORS
• RANDOMIZED PHASE III TRIAL OF NEOADJUVANT IMMUNOTHERAPY WITH RESPONSE ADAPTED TREATMENT VERSUS STANDARD-OF-CARE TREATMENT FOR RESECTABLE STAGE III/IV CUTANEOUS SQUAMOUS CELL CARCINOMA
• A PHASE 2/3, ADAPTIVE, RANDOMIZED, OPEN-LABEL, CLINICAL STUDY TO EVALUATE NEOADJUVANT AND ADJUVANT V940 (MRNA-4157) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) VERSUS STANDARD OF CARE, AND PEMBROLIZUMAB MONOTHERAPY IN PARTICIPANTS WITH RESECTABLE LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA (LA CSCC) (INTERPATH-007)
• NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA VERSUS DEFINITIVE CHEMORADIOTHERAPY WITH SALVAGE SURGERY AS NEEDED(NEEDS TRIAL)
• "A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA."
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE PEMBROLIZUMAB VERSUS PLACEBO AS ADJUVANT THERAPY FOLLOWING SURGERY AND RADIATION IN PARTICIPANTS WITH HIGH-RISK LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA (LA CSCC) (KEYNOTE-630)

View on source registry